Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Sage Therapeutic Com (SAGE)

Sage Therapeutic Com (SAGE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,475,545
  • Shares Outstanding, K 59,494
  • Annual Sales, $ 6,310 K
  • Annual Income, $ -457,890 K
  • 60-Month Beta 1.18
  • Price/Sales 410.46
  • Price/Cash Flow N/A
  • Price/Book 1.87
Trade SAGE with:

Options Overview Details

View History
  • Implied Volatility 52.28% ( +0.50%)
  • Historical Volatility 52.10%
  • IV Percentile 17%
  • IV Rank 9.65%
  • IV High 122.38% on 02/14/22
  • IV Low 44.80% on 08/05/22
  • Put/Call Vol Ratio 0.33
  • Today's Volume 20
  • Volume Avg (30-Day) 358
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 12,056
  • Open Int (30-Day) 10,626

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -2.37
  • Number of Estimates 14
  • High Estimate -2.01
  • Low Estimate -2.64
  • Prior Year -2.12
  • Growth Rate Est. (year over year) -11.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.13 +26.49%
on 11/09/22
44.07 -7.78%
on 12/05/22
+6.76 (+19.95%)
since 11/07/22
3-Month
32.13 +26.49%
on 11/09/22
44.07 -7.78%
on 12/05/22
+1.60 (+4.10%)
since 09/07/22
52-Week
27.36 +48.54%
on 05/09/22
45.74 -11.15%
on 02/09/22
+1.04 (+2.63%)
since 12/07/21

Most Recent Stories

More News
Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression

Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.

BIIB : 292.15 (+0.23%)
GILD : 87.79 (-0.19%)
VRTX : 317.58 (+1.85%)
SAGE : 40.64 (-2.33%)
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment

Atai, Biogen, and Sage are working to develop new treatments for mental illness.

BIIB : 292.15 (+0.23%)
ESALY : 71.3000 (+1.29%)
ATAI : 3.18 (+0.63%)
SAGE : 40.64 (-2.33%)
ARKK : 34.35 (-0.78%)
SEEL : 1.0700 (-6.96%)
CMPS : 10.91 (+5.61%)
MNMD : 2.82 (+1.44%)
CYBN : 0.3224 (-4.42%)
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)...

SAGE : 40.64 (-2.33%)
BIIB : 292.15 (+0.23%)
Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Piper Sandler 34 th...

SAGE : 40.64 (-2.33%)
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the companies will host a joint investor webcast to discuss the planned commercialization approach and opportunity...

SAGE : 40.64 (-2.33%)
BIIB : 292.15 (+0.23%)
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates

EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END

CYBN.NE : 0.430 (-2.27%)
MRVL.VN : 0.150 (+7.14%)
SAGE : 40.64 (-2.33%)
NERV : 3.04 (+1.67%)
ATAI : 3.18 (+0.63%)
CYBN : 0.3224 (-4.42%)
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates

/PRNewswire/ -- FinancialNewsMedia.com News Commentary - Anti-anxiety drugs are medications that are used to treat anxiety disorders that are mainly used to...

MRVL.VN : 0.150 (+7.14%)
SAGE : 40.64 (-2.33%)
NERV : 3.04 (+1.67%)
ATAI : 3.18 (+0.63%)
CYBN : 0.3224 (-4.42%)
Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2022 Healthcare...

SAGE : 40.64 (-2.33%)
Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -6.94% and 3.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

SAGE : 40.64 (-2.33%)
IMPL : 2.87 (+1.06%)
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the third quarter...

SAGE : 40.64 (-2.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product...

See More

Key Turning Points

3rd Resistance Point 43.39
2nd Resistance Point 42.71
1st Resistance Point 41.67
Last Price 40.64
1st Support Level 39.95
2nd Support Level 39.27
3rd Support Level 38.23

See More

52-Week High 45.74
Last Price 40.64
Fibonacci 61.8% 38.72
Fibonacci 50% 36.55
Fibonacci 38.2% 34.38
52-Week Low 27.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar